Archives of Physical Medicine and Rehabilitation
Volume 89, Issue 5 , Pages 982-987 , May 2008

Comparative Impact of 2 Botulinum Toxin Injection Techniques for Elbow Flexor Hypertonia

  • Nathaniel H. Mayer, MD

      Affiliations

    • Department of Physical Medicine and Rehabilitation, Temple University School of Medicine, Philadelphia, PA
    • Moss Rehabilitation Research Institute, Albert Einstein Healthcare Network, Philadelphia, PA
    • Motor Control Analysis Laboratory, MossRehab, Elkins Park, PA.
    • Corresponding Author InformationCorrespondence to Nathaniel H. Mayer, MD, MossRehab, 60 E Township Line Rd, Elkins Park, PA 19027
    • ,
  • John Whyte, MD, PhD

      Affiliations

    • Moss Rehabilitation Research Institute, Albert Einstein Healthcare Network, Philadelphia, PA
    • Department of Rehabilitation Medicine, Thomas Jefferson University, Philadelphia, PA
    • ,
  • Gunilla Wannstedt, MS, PT

      Affiliations

    • Motor Control Analysis Laboratory, MossRehab, Elkins Park, PA.
    • ,
  • Colin A. Ellis, ScB

      Affiliations

    • Moss Rehabilitation Research Institute, Albert Einstein Healthcare Network, Philadelphia, PA

References 

  1. Brashear A, Gordon MF, Elovic E, et al. Botox post-stroke spasticity study group Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395–400
  2. Mayer NH. Choosing upper limb muscles for focal intervention after traumatic brain injury. J Head Trauma Rehabil. 2004;19:119–142
  3. Rousseaux M, Odile K, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol. 2002;249:76–84
  4. Bergfeldt U, Borg K, Kullander K, Julin P. Focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients. J Rehabil Med. 2006;38:166–171
  5. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2001;8:559–565
  6. The WE MOVE Spasticity Study Group. Dosing, administration, and a treatment algorithm for use of botulinum toxin type A for adult-onset muscle overactivity in patients with an upper motoneuron lesion. In:  Mayer NH,  Simpson DM editor. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York: WE MOVE; 2002;p. 154–165
  7. Childers MK, Stacy M, Cooke DL, Stonnington HH. Comparison of two injection techniques using botulinum toxin in spastic hemiplegia. Arch Phys Med Rehabil. 1996;75:462–469
  8. Abbruzzese G, Berardelli A. Neurophysiological effects of botulinum toxin type A. Neurotox Res. 2006;9:109–114
  9. Brin M. Dosing, administration and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Muscle Nerve Suppl. 1997;6:S208–S220
  10. Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck. 1990;12:392–399
  11. Shaari CM, George E, Wu BL, Biller HF, Sanders I. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope. 1991;101:960–964
  12. Childers MK, Kornegay JN, Aoki R, Otaviani L, Bogan DJ, Petroski G. Evaluating motor end-plate-targeted injections of botulinum toxin type A in a canine model. Muscle Nerve. 1998;21:653–655
  13. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve. 1993;16:964–969
  14. Gracies JM, Weisz DJ, Yang BY, Flanagan S, Simpson DM. Impact of botulinum toxin type A (BTX-A) dilution and endplate targeting technique in upper limb spasticity. Ann Neurol. 2002;(Suppl 1):S87
  15. Coërs C, Woolf AL. The innervation of muscle: a biopsy study. Springfield: CC Thomas; 1959;
  16. Coërs C. Structural organization of the motor nerve endings in mammalian muscle spindles and other striated muscle fibers. Am J Phys Med. 1959;38:166–175
  17. Warfel JH. The extremities: muscles and motor points. 5th ed.. Philadelphia: Lea & Febiger; 1985;
  18. Aquilonius SM, Askmark H, Gillberg PG, Nandedkar S, Olsson Y, Stårlberg E. Topographical localization of motor endplates in cryosections of whole human muscles. Muscle Nerve. 1984;7:287–293
  19. Deshpande S, Gormley ME, Carvey JR. Muscle fiber orientation in muscles commonly injected with botulinum toxin: an anatomical pilot study. Neurotox Res. 2006;9:115–120
  20. Gracies JM, Marosszeky JE, Renton R, Sandanam J, Gandevia SC, Burke D. Short-term effects of dynamic lycra splints on upper limb in hemiplegic patients. Arch Phys Med Rehabil. 2000;81:1547–1555
  21. Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol. 1999;6:S23–S35
  22. Ashworth B. Preliminary trial of carisoprodal in multiple sclerosis. Practitioner. 1964;192:540–542
  23. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206–207
  24. Glenn M. Nerve blocks. In:  Glenn MB,  Whyte J editor. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger; 1990;p. 227–258
  25. DeLuca CJ. Surface electromyography: detection and recording. Boston: DelSys; 2002;http://www.delsys.com/Attachments_pdf/WP_SEMGintro.pdfAccessed January 14, 2008
  26. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996;46:1306–1310
  27. Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004;85:1063–1069
  28. Smith S, Ellis E, White S, Moore A. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil. 2000;14:5–13
  29. Bakheit AM, Maynard VA, Curnow J, Hudson N, Koapala S. The relation between Ashworth scale scores and the excitability of the alpha motor neurones in patients with post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry. 2003;74:646–648
  30. Boyd R, Barwood SA, Baillieu CE, Graham HK. Validity of a clinical measure of spasticity in children with cerebral palsy in a randomized clinical trial. Dev Med Child Neurol. 1998;40:7
  31. Leslie GC, Muir C, Part NJ, Roberts RC. A comparison of the assessment of spasticity by the Wartenberg pendulum test and the Ashworth grading scale in patients with multiple sclerosis. Clin Rehabil. 1992;6:41–48
  32. Pandyan AD, Vuadens P, van Wijck FM, Stark S, Johnson GR, Barnes MP. Are we underestimating the clinical efficacy of botulinum toxin (type A)? (Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population). Clin Rehabil. 2002;16:654–660
  33. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW Task force on childhood motor disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics. 2003;111:e89–e97
  34. Katz RT, Rymer WZ. Spastic hypertonia: mechanisms and measurement. Arch Phys Med Rehabil. 1989;70:144–155
  35. Levin MF, Feldman AG. The role of stretch reflex threshold regulation in normal and impaired motor control. Brain Res. 1994;657:23–30
  36. Levin MF, Selles RW, Verheul MH, Meijer OG. Deficits in the coordination of agonist and antagonist muscles in stroke patients: implications for normal motor control. Brain Res. 2000;853:352–369
  37. Banks RW. An allometric analysis of the number of skeletal muscle spindles in mammalian skeletal muscles. J Anat. 2006;208:753–768
  38. Kokkorgiannis T. Somatic and intramuscular distribution of muscle spindles and their relation to muscular angiotypes. J Theor Biol. 2004;229:263–280
  39. Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil. 2002;81:355–363
  40. Gracies J, Weisz D, Bo Y, Flanagan S, Simpson D. Evidence for increased antagonist strength and movement speed following botulinum toxin injections in spasticity. [abstract] Neurology. 2001;56(Suppl 3):A3

 Supported in part by the National Institute on Disability and Rehabilitation Research (grant no. H133A020505) and an educational grant from Allergan Inc.No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated.Reprints are not available from the authors.

PII: S0003-9993(08)00071-3

doi: 10.1016/j.apmr.2007.10.022

Archives of Physical Medicine and Rehabilitation
Volume 89, Issue 5 , Pages 982-987 , May 2008

Article Tools